Dermapharm Holding SE Total Liabilities
Dermapharm Holding SE total liabilities. Based on the latest financial reports, Dermapharm Holding SE (DMP) has total liabilities worth €1.54 Billion EUR (≈ $1.80 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check DMP asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Dermapharm Holding SE (2013–2025)
Total liabilities of Dermapharm Holding SE from 2013 to 2025. This chart illustrates how Dermapharm Holding SE's total liabilities have evolved over time, based on quarterly financial data. Explore Dermapharm Holding SE (DMP) long-term investment share to see how much of total assets are deployed in long-term investments.
Dermapharm Holding SE Competitors by Total Liabilities
The table below lists competitors of Dermapharm Holding SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aadhar Housing Finance Ltd
NSE:AADHARHFC
|
India | Rs181.89 Billion |
|
North West Company Inc
TO:NWC
|
Canada | CA$782.13 Million |
|
CleanSpark Inc
NASDAQ:CLSK
|
USA | $1.94 Billion |
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
Argentina | AR$2.70 Trillion |
|
Grupo Profuturo S.A.B. de C.V
MX:GPROFUT
|
Mexico | MX$152.08 Billion |
|
Mesoblast Ltd
NASDAQ:MESO
|
USA | $204.67 Million |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
USA | $1.66 Billion |
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
China | CN¥1.39 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Dermapharm Holding SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Dermapharm Holding SE (DMP) total assets.
Liquidity & Leverage Metrics
Dermapharm Holding SE Total Liabilities Ratios Explained
Dermapharm Holding SE total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dermapharm Holding SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dermapharm Holding SE (2013–2025)
The table below shows the annual total liabilities of Dermapharm Holding SE from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.50 Billion ≈ $1.76 Billion |
+2.12% |
| 2024-12-31 | €1.47 Billion ≈ $1.72 Billion |
-8.91% |
| 2023-12-31 | €1.62 Billion ≈ $1.89 Billion |
+83.52% |
| 2022-12-31 | €880.34 Million ≈ $1.03 Billion |
-2.95% |
| 2021-12-31 | €907.13 Million ≈ $1.06 Billion |
+0.81% |
| 2020-12-31 | €899.81 Million ≈ $1.05 Billion |
+18.34% |
| 2019-12-31 | €760.38 Million ≈ $888.97 Million |
+69.54% |
| 2018-12-31 | €448.50 Million ≈ $524.34 Million |
+31.29% |
| 2017-12-31 | €341.62 Million ≈ $399.39 Million |
+36.16% |
| 2016-12-31 | €250.89 Million ≈ $293.32 Million |
-0.53% |
| 2015-12-31 | €252.22 Million ≈ $294.88 Million |
-14.96% |
| 2014-12-31 | €296.59 Million ≈ $346.74 Million |
-3.90% |
| 2013-12-31 | €308.62 Million ≈ $360.80 Million |
-- |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers br… Read more